BackZhejiang Cheng Yi Pharmaceutical , Ltd. Overview

Zhejiang Cheng Yi Pharmaceutical , Ltd. Receivables

Track Zhejiang Cheng Yi Pharmaceutical , Ltd.'s receivables ($67M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$67.49M
↓ 12.66% YoYΔ $-9.78M vs prior year quarter

Peer trimmed avg / median

Loading

Zhejiang Cheng Yi Pharmaceutical , Ltd. Receivables History

Loading

Zhejiang Cheng Yi Pharmaceutical , Ltd. vs. peers: Receivables Comparison

Loading

Zhejiang Cheng Yi Pharmaceutical , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zhejiang Cheng Yi Pharmaceutical , Ltd. (603811.SS) FAQ

As of the most recent data (June 2026), 603811.SS shows a receivables of $67M. That compares with $77M in the prior-year period — down 12.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 603811.SS's receivables is now $67M (was $77M) — a 12.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Zhejiang Cheng Yi Pharmaceutical , Ltd. is outperforming or lagging.

Tracking 603811.SS's receivables over time shows whether Zhejiang Cheng Yi Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $67M That compares with $77M in the prior-year period — down 12.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Zhejiang Cheng Yi Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $67M) with ownership activity and broader fundamentals.